Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
In this multi-center, randomized, open-label, prospective clinical trial, a total of 60
relapsed/refractory AML patients will be randomized into 2 groups. In the experimental arm,
patients receive IAC regimen. In the control arm, patients receive other physician-directed
regimen. The primary end point is complete remission rate.